Cargando…
Real-World Safety of Intravitreal Bevacizumab and Ranibizumab Treatments for Retinal Diseases in Thailand: A Prospective Observational Study
BACKGROUND: There is very limited evidence examining serious systemic adverse events (SSAEs) and post-injection endophthalmitis of intravitreal bevacizumab (IVB) and intravitreal ranibizumab (IVR) treatments in Thailand and low- and middle-income countries. Moreover, findings from the existing trial...
Autores principales: | Sangroongruangsri, Sermsiri, Chaikledkaew, Usa, Kumluang, Suthasinee, Wu, Olivia, Geue, Claudia, Ratanapakorn, Tanapat, Leelahavarong, Pattara, Ingsrisawang, Lily, Ruamviboonsuk, Paisan, Taweebanjongsin, Wongsiri, Choovuthayakorn, Janejit, Singalavanija, Apichart, Hanutsaha, Prut, Kulvichit, Kittisak, Ratanapojnard, Thitiporn, Wongsawad, Warapat, Teerawattananon, Yot |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6153972/ https://www.ncbi.nlm.nih.gov/pubmed/30069864 http://dx.doi.org/10.1007/s40261-018-0678-5 |
Ejemplares similares
-
Correction to: Real-World Safety of Intravitreal Bevacizumab and Ranibizumab Treatments for Retinal Diseases in Thailand: A Prospective Observational Study
por: Sangroongruangsri, Sermsiri, et al.
Publicado: (2019) -
A real-world study of effectiveness of intravitreal bevacizumab and ranibizumab injection for treating retinal diseases in Thailand
por: Kumluang, Suthasinee, et al.
Publicado: (2019) -
Cost-Utility Analysis of Drug Treatments in Patients with Polypoidal Choroidal Vasculopathy in Thailand
por: Sangroongruangsri, Sermsiri, et al.
Publicado: (2021) -
Cost-Utility Analysis of Deep Learning and Trained Human Graders for Diabetic Retinopathy Screening in a Nationwide Program
por: Srisubat, Attasit, et al.
Publicado: (2023) -
The use of comparative effectiveness research to inform policy decisions on the inclusion of bevacizumab for the treatment of macular diseases in Thailand’s pharmaceutical benefit package
por: Anothaisintawee, Thunyarat, et al.
Publicado: (2012)